NasdaqGS - Delayed Quote USD

OPKO Health, Inc. (OPK)

Compare
1.4600 -0.0100 (-0.68%)
At close: October 11 at 4:00 PM EDT
1.4897 +0.03 (+2.03%)
Pre-Market: 8:31 AM EDT
Loading Chart for OPK
DELL
  • Previous Close 1.4700
  • Open 1.4600
  • Bid 1.4500 x 1800
  • Ask 1.4800 x 2500
  • Day's Range 1.4200 - 1.5000
  • 52 Week Range 0.8500 - 1.7500
  • Volume 3,098,839
  • Avg. Volume 3,380,789
  • Market Cap (intraday) 1.01B
  • Beta (5Y Monthly) 1.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3300
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.96

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.

www.opko.com

3,930

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OPK

View More

Performance Overview: OPK

Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

OPK
3.31%
S&P 500
21.91%

1-Year Return

OPK
2.67%
S&P 500
33.43%

3-Year Return

OPK
60.43%
S&P 500
32.42%

5-Year Return

OPK
28.78%
S&P 500
97.92%

Compare To: OPK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OPK

View More

Valuation Measures

Annual
As of 10/11/2024
  • Market Cap

    1.01B

  • Enterprise Value

    1.24B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.48

  • Price/Book (mrq)

    0.72

  • Enterprise Value/Revenue

    1.73

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -33.93%

  • Return on Assets (ttm)

    -8.09%

  • Return on Equity (ttm)

    -16.59%

  • Revenue (ttm)

    716.37M

  • Net Income Avi to Common (ttm)

    -243.1M

  • Diluted EPS (ttm)

    -0.3300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    40.58M

  • Total Debt/Equity (mrq)

    19.31%

  • Levered Free Cash Flow (ttm)

    -76.7M

Research Analysis: OPK

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 182.19M
Earnings -10.3M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

2.00
3.96 Average
1.4600 Current
8.50 High
 

Company Insights: OPK

Research Reports: OPK

View More
  • Daily – Vickers Top Insider Picks for 03/15/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/14/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/13/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/12/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch